2 results
Approved WMOCompleted
The primary objective is to show that the ORION SYSTEM is safe and performs as intended.
Approved WMOCompleted
To evaluate the safety and efficacy of abicipar (2 mg), compared to 0.5 mg ranibizumab in treatment-naïve patients with neovascular AMD.